Molecular Partners AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, revenue was CHF 3.47 million compared to CHF 184.54 million a year ago. Net loss was CHF 30.77 million compared to net income of CHF 148.61 million a year ago. Basic loss per share from continuing operations was CHF 0.94 compared to basic earnings per share from continuing operations of CHF 4.59 a year ago. Diluted loss per share from continuing operations was CHF 0.94 compared to diluted earnings per share from continuing operations of CHF 4.48 a year ago.